ReviewFrontiers in human neuroscience2026
Assessing the efficacy and safety of rTMS, tDCS, and DBS in treating auditory hallucinations: a scoping review.
Review in Frontiers in human neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Auditory hallucinations (AH)-the perception of sound in the absence of any external auditory stimulus-are among the most clinically significant and personally distressing symptoms encountered in psychiatry and neurology. Although AH is canonically associated with schizophrenia spectrum disorders, where it affects 60-80% of patients at some point in the illness course, it also emerges in major depressive disorder with psychotic features, bipolar disorder, post-traumatic stress disorder, borderline personality disorder, substance-induced psychoses, and a range of neurological conditions including epilepsy, Parkinson's disease, Lewy-body dementia, and acquired brain injury. Patients with treatment-resistant AH (TR-AH) experience a substantial decline in their quality of life and face increased economic burden. The limitations of existing pharmaceutical treatments have spurred researchers to develop and assess neuroregulation techniques that can directly target abnormal neural circuits involved in the pathophysiology of AH. This review consolidates the current research findings of stimulation-based treatment methods for AH and aims to conduct an evidence-based evaluation of efficacy, safety, and practical feasibility of three neuromodulation methods: repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), and deep brain stimulation (DBS). By making a comparison of these three methods, this review presents their respective risks and strengths and offers implications for future research direction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.